NCT04958434

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated Phase 1 Last updated 23 October 2023

What this trial tests

Phase 1 trial testing TST005 in Locally Advanced or Metastatic Cancers in 19 participants. Terminated before completion.

Timeline

11 June 2021

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Suzhou Transcenta Therapeutics Co., Ltd.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	11 June 2021
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	3 locations across United States

Drugs / interventions tested

• TST005 — full drug profile →

Conditions studied

• Locally Advanced or Metastatic Cancers — all drugs for Locally Advanced or Metastatic Cancers →
• Metastatic Human Papillomavirus-Related Malignant Neoplasm — all drugs for Metastatic Human Papillomavirus-Related Malignant Neoplasm →

Sponsor

Suzhou Transcenta Therapeutics Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Locally Advanced or Metastatic Cancers or Metastatic Human Papillomavirus-Related Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting TGF-β signal transduction for fibrosis and cancer therapy.
   Peng D, Fu M, Wang M, Wei Y, et al · · 2022 · cited 752× · PMID 35461253 · DOI 10.1186/s12943-022-01569-x
2. TGF-beta signal transduction: biology, function and therapy for diseases.
   Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
3. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
   Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
4. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
   Lian G, Mak TS, Yu X, Lan HY. · · 2021 · cited 44× · PMID 35008589 · DOI 10.3390/ijms23010164
5. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
   Li T, Niu M, Zhou J, Wu K, et al · · 2024 · cited 31× · PMID 38475778 · DOI 10.1186/s12964-024-01562-5
6. Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
   Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
7. Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.
   Masuda H. · · 2025 · cited 11× · PMID 40707476 · DOI 10.1038/s41420-025-02566-x
8. TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance.
   Johansen AM, Forsythe SD, McGrath CT, Barker G, et al · · 2024 · cited 11× · PMID 38916900 · DOI 10.1158/1078-0432.ccr-24-0468